A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body

Sponsor
Boehringer Ingelheim
Study ID
NCT06772532
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • BI 456906 - Formulation A — COMBINATION_PRODUCT
    Formulation A
  • BI 456906 - Formulation B — DRUG
    Formulation B
  • BI 456906 - Formulation C — DRUG
    Formulation C

Study Details

The main objective of this trial is to investigate relative bioavailability of BI 456906 formulation B and BI 456906 formulation C vs. BI 456906 formulation A.

Key Dates

Start date
Feb 10, 2025
Status verified
Mar 2026
Primary completion
May 29, 2025
Completion
Jun 10, 2025

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment sequence R-T2-T1
    T1: BI 456906 formulation B T2: BI 456906 formulation C R: BI 456906 formulation A
  • Experimental: Treatment sequence T1-R-T2
  • Experimental: Treatment sequence T2-T1-R

Primary Outcome Measure

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) [ Time Frame: Up to 22 days ]

Related Studies